Summary Germ cell development is influenced by activin and inhibin, which are produced by Sertoli cells. Activin also affects differentiation of mouse embryonal carcinoma cells, which, to a certain extent, resemble the embryonal carcinoma component of germ cell tumours. Therefore, the expression of inhibin/activin subunits, of activin receptors and of the activin-binding protein follistatin was studied in testicular germ cell tumours, using RNAase protection assays. Testicular germ cell tumours of adolescents and adults (TGCTs) and spermatocytic seminomas expressed activin type and type 11 receptors (ActRi and ActRII respectively). Seminomas expressed significantly lower levels of ActRIIA (P<0.05, Mann-Whitney U-test) and higher levels of ActRIA (P<0.05) and ActRIB (P<0.05) compared with non-seminomas. All tumours expressed inhibin n-subunit transcripts, which are a prerequisite for activin synthesis. Non-seminomas contained significantly higher levels of the inhibin PA subunit (P<0.001) compared with seminomas. No activin PC subunit transcripts could be demonstrated by RNAase protection. Inhibin a-subunit expression was absent in the spermatocytic seminomas, in six out of nine seminomas and in 10 out of 11 nonseminomas. Follistatin was expressed predominantly in non-seminomas and spermatocytic seminomas. This expression of activin type and type 11 receptors in combination with expression of inhibin 5-subunits indicates that activin may act as a para-or autocrine factor in the regulation of growth and differentiation of tumours of human germ cells.
Testicular tumours account for 1-3% of all malignancies in Caucasian men, with a peak incidence between 15 and 45 years of age. In this age group, it is the most frequently encountered malignancy (Forman and M0ller, 1994) . Approximately 95% of the testicular tumours originate from germ cells (Ulbright, 1993; Forman and M0ller, 1994) .
Testicular germ cell tumours of adolescents and adults (TGCTs) can be subdivided into two groups of about equal numerical importance: seminomas and non-seminomas (Ulbright, 1993) . Both these groups develop from intratubular germ cell neoplasia (carcinoma in-situ or CIS) (Skakkebek et al, 1987) , but seminomas and non-seminomas differ in histology and clinical behaviour, with the non-seminomas being the more aggressive tumours (Oosterhuis et al, 1993) . Histologically, non-seminomas are classified as embryonal carcinomas, teratomas, choriocarcinomas and yolk sac tumours (Mostofi, 1980; Ulbright, 1993) . These components originate from pluripotent embryonal carcinoma cells (Andrews et al, 1987) and may occur as the only cell type or may be intermixed. In contrast to the non-seminomas and the classical seminoma, the spermatocytic seminoma does not originate from CIS Skakkebaek et al, 1987) but is thought to arise from neoplastic germ cells at a stage of maturation between spermatogonia and spermatocytes (Talerman, 1980; Muller et al, 1987; Eble, 1994) . Spermatocytic seminoma represents 1-2% of all testicular tumours, generally occurs in men over 50 years of age and rarely metastasizes (Muiller et al, 1987; Eble, 1994) .
Activin and inhibin are members of the transforming growth factor beta (TGF-1) family of growth and differentiation factors, which were initially detected in and isolated from gonadal fluids (de Jong and Sharpe, 1976; Mason et al, 1985; Ling et al, 1986; Vale et al, 1986) . Activin is a homo-or heterodimer of two highly homologous inhibin [3-subunits ([A and [B) , which exerts its action through binding to specific membrane-spanning serine/threonine kinase receptors. The activin type II receptors, either activin receptor IIA (ActRIIA) or IIB (ActRIIB), bind activin; one of the activin type I receptors (ActRIA or ActRIB) is then recruited into the complex and is activated by phosphorylation (Caircamo et al, 1994; Mathews, 1994; Wrana et al, 1994) . The biological effects of activin can be counteracted by the activin-binding protein follistatin (Michel et al, 1993) or by inhibin, which is a dimer of an inhibin ax-and [-subunit . In the testis, spermatogenesis depends on factors produced by Sertoli and Leydig cells. Inhibin and activin are secreted by Sertoli cells ( de Jong, 1988; de Winter et al, 1993) , while activin can also be produced by peritubular myoid cells (de Winter et al, 1994) . Germ cells express activin receptors (Kaipia et al, 1991; de Winter et al, 1992; Cameron et al, 1994) , bind activin and inhibin , and respond to inhibin and activin administration (van Dissel-Emiliani et al, 1989; Mather et al, 1990) .
The human non-seminomatous embryonal carcinoma cell line Tera-2 (Andrews, 1988) expresses activin type II receptors (de Jong et al, 1993) and activin type I receptors (RHN van Schaik, unpublished results). Transcript levels for ActRIIB and follistatin change dramatically after retinoic acid treatment, suggesting changes in sensitivity for activin upon cell differentiation. Activin itself stimulates the expression of growth and differentiation factor 3 (hGDF-3) in this cell line (Caricasole et al, submitted) , confirming that a functional activin signalling pathway exists in Tera-2 cells. In mouse embryonal carcinoma cells, activin was shown to act as a growth factor in undifferentiated P19 cells (Hashimoto et al, 1990) , while retinoic acid-induced differentiation of these cells could be blocked by activin (Hashimoto et al, 1990; van den Eijnden-van Raaij et al, 1991) . Furthermore, inhibin immunoreactivity has been demonstrated in clinical samples of human TGCTs (de Jong et al, 1990 ). These observations led us to investigate whether clinical germ cell tumours express activin receptors and inhibin/activin subunits. We demonstrated the expression of activin type I and type II receptors, in combination with inhibin PA and ,B subunits and follistatin mRNAs.
MATERIALS AND METHODS

Tumour material and RNA isolation
Human testicular tumour material, collected during operation at the collaborating hospitals, was divided into two representative portions. One of these portions was snap frozen in liquid nitrogen, while the other portion was fixed in 4% buffered formalin and embedded in paraffin. Tumours were classified according to the recommendations of the World Health Organization (Mostofi et al, 1987) , as described previously (Oosterhuis et al, 1989) . In this study, nine seminomas, 11 non-seminomas and two spermatocytic seminomas were included. The non-seminoma group consisted of one pure embryonal carcinoma (EC), two yolk sac tumours (YS), one mature teratoma (MT), one immature teratoma (IT), three tumours with two components (one EC/YS and two MT/YS) and three mixed tumours consisting of EC/IT/MT/YS plus trophoblastic giant cells in combination with a seminoma component. In these mixed tumours, the non-seminoma component could clearly be distinguished macroscopically from the seminoma component; only the non-seminoma component was used in this study. Frozen tissue (-80°C) was pulverized in liquid nitrogen, followed by RNA isolation using TRIzol reagent (Gibco BRL, Gaithersburg, MD, USA), according to the manufacturer's protocol. RNA was dissolved in RNAase-free water and its concentration and purity were determined by optical density measurements at 260 and 280 nm. Normal testis RNA was isolated from tissue provided by the Dr Daniel den Hoed Cancer Center or was obtained commercially from ClonTech (Palo Alto, CA, USA).
RT-PCR
cDNA was synthesized from total RNA by a random hexamerprimed reverse transcriptase reaction using AMV reverse transcriptase (Promega, Madison, WI, USA), as described by Sambrook et al (1989) . Oligonucleotide primers (Pharmacia, Breda, The Netherlands) are based on published human sequences and are separated by at least one intron in the genomic DNA. Nucleotides printed in bold represent mismatches to the human sequence, either to generate restriction sites or because primers based on the rat/mouse sequence were used as the human sequence was not known at the time (ActRIIB). Primers used are as follows: ActRIA, GAGTATGGCA CTATCGAAGG GCT and GAAG-ATCTTC ACGGCAACAT TTT; ActRIB, ATCGACTTGA GGGTGCCC and GAATATTTTC ACAGCCACAT CAC; ActRIIA, CAGGGAACTG GATATCTAGA GAGAACTTC and TGGTCCTGGG TCTCGAGTAG GAACAAGTAC; ActRIIB, CGAATTCCGC TGCTGCCCAT TGGAGGC and TGTAA-GCTTG TGGCCCTCAC CACGACACC; the inhibin a-subunit, CGAATTCTAG CAGGGCCAGG TGAGCT and TGTAA-GCTTG TGGCTGGGAA AAGGAT; PA-subunit, TTGCTT-TGGC TGAGAGGAT and GCCCTTCTTT TTCCCTTCC; fB-subunit, CGAATTCATC AGCTTCGCCG AGAC and TGTAAAGCTT GCACTGTCAG GCGCAGCCGC; [C-subunit, CTTGGACAAG CTGCACCTC (gift from Dr G Hotten, BioPharm, Germany) and TAGAAGCTTC TGTAGGGGCG TGTTTC; follistatin, CGAATTCCGA ATGAACAAGA AGAAC and TGTAAGCTTC TCCCAACCTT GAAATCCC. Actinprimers (AAGAATTCCT ATGTGGGCGA CGAG and TAGAAGCTTT TGCGGTGGAC GATGGAG) were used as a control to validate RNA integrity, the reverse transcriptase reaction and the polymerase chain reaction (PCR). PCR reactions were cycled 35 times with a cycle profile of 1 min at 94°C, 2 min at 50°C and 2 min at 72°C, using 0.2 units of SuperTaq (HT/Biotechnology, Cambridge, UK) per reaction. Reaction products were analysed by agarose gel electrophoresis followed by Southern blotting and hybridization with the corresponding rat inhibin subunit cDNA probes (Esch et al, 1987) , a rat ActRIIA cDNA probe (de Winter et al, 1992) or a rat ActRIIB cDNA probe (JG Wesseling, unpublished) corresponding to nucleotides 683-1147 (Feng et al, 1993) . Activin type I receptor products were hybridized with human ActRIA or ActRIB cDNA probes (ten Dijke et al, 1993) ; follistatin and activin PC subunit PCR products were detected using cloned human partial cDNAs (see below).
cDNA cloning cDNAs encoding part of the human inhibin subunits, activin receptors and follistatin were cloned after reverse transcriptase-polymerase chain reaction (RT-PCR) with AmpliTaq (Roche Molecular Systems, Branchburg, NJ, USA). Human ActRIIA (nucleotides 132-791; Donaldson et al, 1992) and inhibin f.A subunit (nucleotides 309-946; Mason et al, 1986 ) cDNAs were cloned from K562 cells; ActRIIB (nucleotides 429-947; Hilden et al, 1994) and inhibin 1B subunit (nucleotides 263-1073; Mason et al, 1986 ) cDNAs were cloned from human testis. The inhibin ax-subunit cDNA (nucleotides 125-411; Mayo et al, 1986 ) was cloned from genomic DNA, and follistatin cDNA (nucleotides 345-819; Shimasaki et al, 1988) was cloned from placental RNA.
For the activin PC subunit, a partial cDNA was cloned corresponding to nucleotides 824-1240 (Hotten et al, 1995) , using PCR on K562 genomic DNA. All cDNAs were subcloned in pBluescript KS(-) (Stratagene, La Jolla, CA, USA) and checked by sequencing. For the activin type I receptors, a DraIIIXbaI fragment (nucleotides 1261-1692; ten Dijke et al, 1993) of ActRIA and an ApaI-ApaI fragment of ActRIB (nucleotides 73-361; GenBank, accession number Z22536) were subcloned in pBluescript KS(-).
RNAase protection assay cDNA clones were digested with appropriate restriction enzymes and 32P-labelled RNA probes were made by transcription in the presence of [32P]UTP using T3 or T7 RNA polymerase (Stratagene). The cRNA probes protect nucleotides 602-791 for ActRIIA (Donaldson et al, 1992) , nucleotides 631-947 for British Joumal of Cancer (1997) 76(9) Figure 1 RNAase protection analyses of (A) activin receptors and (B) inhibin subunits and follistatin in germ cell tumours. Five micrograms of RNA was hybridized with the probes indicated. Representative data for seminomas (SE), non-seminomas (NS) and spermatocytic seminomas (SP) are shown. Results were visualized using a Phosphorlmager. Normal testis (NT) RNA served as a control. Actin signal is shown at a 100-fold decreased intensity compared with the other signals ActRIIB (Hilden et al, 1994) , nucleotides 126-411 for the inhibin a-subunit (Mayo et al, 1986) , nucleotides 702-946 for the inhibin PA subunit (Mason et al, 1986) , nucleotides 845-1073 for the inhibin PB subunit (Mason et al, 1986 ) and nucleotides 508-819 for the follistatin transcript (Shimasaki et al, 1988 Figure IA) ; transcription levels were quantified and expressed relative to gamma actin (Figure 2 ). All four activin receptors were detected in seminomas, non-seminomas and spermatocytic seminomas. Seminomas contained significantly less ActRIIA mRNA than non-seminomas [3.0 ± 0.4 vs 5.0 ± 0.7 relative units (RU) respectively; P < 0.05], whereas ActRIIB mRNA expression levels were not different. RNAase protection assays failed to detect expression of ActRIIB in one non-seminoma (MT). The transcript levels for ActRIB mRNA in seminomas were significantly higher (P < 0.05) than those in non-seminomas (10.5 ± 2.0 vs 4.0 ± 0.9 RU respectively), while, in addition, a significant difference was found for ActRIA (5.4 ± 1.1 vs 2.5 ± 0.9 RU respectively; P < 0.05). RNAase protection assays failed to detect expression of ActRIA in three non-seminomas (one embryonal carcinoma and two mixed tumours). Expression levels in spermatocytic seminomas were similar to those found in seminomas and non-seminomas for ActRIA, while ActRIIB expression was relatively high. ActRIB and ActRIIA mRNA expression levels resembled those of non-seminomas.
Within seminomas or non-seminomas, significant correlations were found between the expression of ActRIIA and type IA and IB receptors: for seminomas r = 0.821 (P < 0.005) and r = 0.929 (P < 0.0005) respectively; for non-seminomas, r = 0.673 (P < 0.05) and r = 0.533 (P < 0.05) respectively (Figure 3) . In non-seminomas, ActRIIB expression was significantly correlated with ActRIB expression (r = 0.649; P < 0.025) (results not shown) but not with ActRIA (r = 0.019).
Inhibin subunits and follistatin
Preliminary experiments using RT-PCR for inhibin subunits revealed the presence of transcripts encoding both inhibin PA and 1B subunits but not inhibin a-subunit (results not shown).
Expression of the activin PC subunit, a recently cloned cDNA showing close homology with the inhibin 3-subunits (Hotten et al, 1995) , was found by RT-PCR in normal testis, while a weaker signal was obtained in the two seminomas but not in the two nonseminomas tested. RNAase protection assays performed on the 22 testicular tumours confirmed the presence of inhibin PA and 3B subunit transcripts in seminomas and non-seminomas (Figure 1 B) .
Expression of the PA subunit transcript in the non-seminomas ranged from 2.3 and 3.0 RU for one mature teratoma/yolk sac tumours and the immature teratoma, respectively, to approximately 28 RU for one yolk sac tumour and one mixed tumour. The expression levels in the non-seminomas were significantly British Journal of Cancer (1997) 76(9) Kaipia et al, 1993; Cameron et al, 1994) and in the human teratocarcinoma cell line Tera-2 ( de Jong et al, 1993; RHN van Schaik, unpublished results) . Our inability to detect ActRIIB expression in one non-seminoma, a mature teratoma, is in line with the down-regulation of ActRIIB mRNA levels when Tera-2 cells are differentiated by retinoic acid (de Jong et al, 1993 ). Significant differences were found between the expression of ActRIA, ActRIB and ActRIIA in seminomas and non-seminomas, giving rise to different ActRIA/ActRIB and ActRIIA/ActRIIB receptor transcript ratios in these tumours. In the embryonal carcinoma and in two mixed tumours, ActRIA mRNA levels could not be detected by RNAase protection analysis. As differences in affinity for activin (Attisano et al, 1992) and inhibin (Martens et al, 1997) have been reported for the type II receptors, and as the biological response to activin depends on the type I receptor involved in the type 11-type I receptor complex (Caircamo et al, 1994) , the different receptor mRNA ratios found may indicate differences between the tumours in their response to activin.
An important issue in activin research is the regulation of receptor expression and the question of whether there is a preference for interaction between a specific type I and type II receptor. For this reason, we looked at correlations between expression of activin receptors. ActRIA and ActRIB expression both correlated with ActRIIA expression in seminomas and non-seminomas, suggesting that expression of these transcripts may depend on common factors in these tumours. Interestingly, the slopes of the regression lines for seminomas and non-seminomas differ. Possibly, the histologically heterogeneous non-seminomas contain cell types with a different activin type I-type II receptor ratio. Results of in situ hybridization may resolve this point.
Inhibin PA and PB subunit mRNA expression in the normal testis is restricted to Sertoli and peritubular myoid cells and has not been described in germ cells. The expression of these subunits in all tumours of deranged germ cells investigated, i.e. TGCTs and spernatocytic seminomas, suggests that these tumours have acquired the potential to produce activin and may therefore indicate the existence of an autocrine system for activin. This is especially the case in the more aggressive non-seminomas, which were shown to express relatively high levels of inhibin PA subunit mRNA. The recently described cloning of the activin PC subunit cDNA (Hotten et al, 1995) , which showed homology to the inhibin PA and ,B subunits, prompted us to examine its expression in TGCTs. Using activin PC subunit-specific primers, followed by identification of the reaction products by hybridization with a 32P-labelled human activin PC subunit probe, we found signal in normal testis and a weaker signal in the two seminomas analysed. This expression in the normal testis is in agreement with a recent report on rat testis, in which a 1.8-kb mRNA for activin PC mRNA was found on a Northern blot containing poly(A)+ RNA of round spermatids (Loveland et al, 1996) . However, we were unable to detect activin PC subunit mRNA in the normal human testis by (-) P1C subunit in the testis is substantially lower than in the liver. This is in agreement with the absence of an activin PC signal in a
Northern blot of adult mouse tissues (Lau et al, 1996) . Therefore, the absence of an activin ,BC subunit signal in the RNAase protection for the TGCTs led us to conclude that activin PC is not expressed in substantial amounts in these tumours. The combined expression of inhibin a-and jB subunit expression in one non-seminoma may be the result of extra-embryonal differentiation, because expression of these subunits has been described in trophoblastic cells and fetal membranes (Qu and Thomas, 1995) . Apparently, this is not a general phenomenon as the other mature teratoma/yolk sac tumour in our panel did not give rise to relatively high expression levels for inhibin a-and fiB subunits; in addition, pure yolk sac or mature teratoma tumours were negative for inhibin a-subunit mRNA. Evidence for inhibin immunoreactivity in homogenates of non-seminomas has been presented earlier (de Jong et al, 1990) , indicating that inhibin synthesis can occur in non-seminomas. As n-subunit expression is found in all tumours investigated so far, while inhibin a-subunit is expressed in only a few, one could speculate that a-subunit synthesis occurs at a later stage in the development of some tumours, thereby affecting activin-induced differentiation processes. More research is necessary to elucidate the interplay between inhibin and activin in TGCT differentiation processes.
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Expression of the activin-binding protein follistatin, like the inhibin PA-subunit mRNA, was observed predominantly in nonseminomas. In cultured rat pituitary cells, activin was found to stimulate follistatin production (Bilezikjian et al, 1993) , which is thought to be an effect of activin on follistatin mRNA levels (DePaolo et al, 1993) . However, the correlations between follistatin and inhibin PA mRNA expression (r = 0.457), follistatin and inhibin fB mRNA (r = 0.040) or between follistatin and inhibin (PA + fB) mRNA (r = 0.346) did not reach statistical significance (P> 0.05). As the production of follistatin will inhibit activin action, and thus interfere with the correlation between expression of 3-subunits and biologically active activin, the described approach is probably too simplistic to identify effects of activin on follistatin expression in TGCTs. In seminomas, follistatin expression was at the detection limit of our assay, except for one tumour in which follistatin mRNA levels exceeded the average expression level found in the other seminomas by almost a factor of 10. This tumour also differed from the other seminomas for mRNA levels for activin type I and type II receptors which were a factor of 4-12 lower than the average for seminomas; in addition, expression of inhibin PA and fB subunits was substantially lower. Retrospective investigation showed that this tumour was strongly vimentin positive and therefore differed from the classical seminoma. We are not aware to date, however, of any differences in clinical behaviour between vimentin-positive and classical seminomas.
Indications for the presence of biologically active activin in TGCTs are at present only indirect. Expression of the tyrosine kinase c-kit was reported in 80% of seminomas, but only in 7% of non-seminomas (Strohmeyer et al, 1991) . Because it was shown that c-kit mRNA expression in mouse erythroleukaemia cells can be down-regulated by activin (Hino et al, 1995) , these observations are in line with higher bioactive activin levels in non-seminomas compared with seminomas. Secondly, the mRNA expression of hGDF-3, which can be stimulated by activin in the human embryonal carcinoma-derived Tera-2 cells, was significantly higher in non-seminomas than in seminomas (Caricasole et al, submitted).
As activin receptors, inhibin subunits and follistatin are expressed in germ cell tumours, activin may be involved in testicular germ cell tumour development. Because CIS is found at sites normally occupied by spermatogonia (Skakkebak et al, 1987) , these sites are likely to provide the specialized conditions required for their survival and proliferation. Based upon our results, we hypothesize that activin synthesis provides autocrine/paracrine conditions for tumour progression, making the germ cell neoplasms independent from Sertoli cell-secreted factors. The relatively high expression of inhibin PA subunit mRNA in non-seminomas compared with seminomas may thus be related to the higher malignant potential of these TGCTs (Oosterhuis et al, 1993) . Interestingly, the spermatocytic seminomas that we included in our study also expressed inhibin 3-subunits, indicating that activin production may in general be favourable for autonomously proliferating germ cells. Because of the very low incidence rate of these neoplasms, we were unable to investigate additional tumours. The observed differences between seminomas and non-seminomas further raise the question of whether these differences precede the development of CIS into non-seminomas or seminomas or are merely the result of this process. As activin expression is present during mouse embryonal development (Albano et al, 1993; Feijen et al, 1994) , the increased activin mRNA expression found in nonseminomas compared with seminomas could also be the result of the malignant gonocytes acquiring pluripotency and entering differentiation. In that case, the extent of activin synthesis by a non-seminoma may determine the differentiation status of the tumour, thereby affecting tumour progression and prognosis, as a high percentage of embryonal carcinoma is prognostically unfavourable (Moul et al, 1994) . Additional research to elucidate expression of inhibin subunits, activin receptors and follistatin in the different tumour components of non-seminomas by in situ hybridization and immunohistochemistry are currently being undertaken to elucidate these aspects.
